Researchers Unveils Promising Results of Epidermolysis Bullosa Study: A Breakthrough in Dermatological Care
Canada: A leading biopharmaceutical company dedicated to innovative cannabinoid-based therapies, Avicanna Inc., has recently unveiled the results of a groundbreaking study focused on patients suffering from Epidermolysis Bullosa (EB). This debilitating genetic disorder, characterized by fragile skin prone to blistering and tearing, has long posed significant challenges for both patients and healthcare providers. However, Avicanna's latest research offers a ray of hope, showcasing the potential of cannabinoid-based treatments in managing EB symptoms and improving patients' quality of life.
The company announced the completion of the retrospective observational real-world evidence study (“Study”) using its RHO Phyto branded Ultra CBD Topical Cream on patients with epidermolysis bullosa.
The study, led by Elena Pope, MD, M.Sc., FRCPC, Head of Dermatology at The Hospital for Sick Children in Toronto, evaluated the efficacy and tolerability of RHO Phyto branded Ultra CBD Topical Cream in patients with epidermolysis bullosa.
The retrospective cohort study evaluated the reported and documented responses related to wound healing, itch, and pain endpoints through images for study purposes to evaluate and examine RHO Phyto branded Ultra CBD Topical Cream's effect on wound healing. The RHO Phyto branded Ultra CBD Topical Cream is an oil-based 3% CBD localized cream developed to target dermatology conditions.
The study involved 20 patients (6 female patients and 14 male patients) with an average age of 17.3 years with various subtypes of epidermolysis bullosa, including simplex (30%), dystrophic (60%), and junctional (10%).
The following were the key findings of the study:
- After one month of daily application of the 3% CBD Cream, 55% of patients reported improvements in wound healing, and 45% displayed wound stability.
- Evaluation of self-reported itch and pain scores were reported in 65% and 50% of patients, respectively.
- Of the study participants evaluated, 45% continued to use treatment over six months.
The study results will be presented at Avicanna’s symposium on May 13th by Dr. Camila Sofia Arriaga Egnen from The Hospital for Sick Children.
Dr. Elena Pope stated, “Using RHO Phyto branded Ultra CBD Topical Cream is a novel topical therapeutic option for EB patients, providing symptom relief and potentially aiding in wound healing with good tolerability. Further prospective studies are needed to substantiate these findings.”
“We are pleased to see the Study reporting early positive results for RHO Phyto branded Ultra CBD Topical Cream in a patient population that continues to seek treatment for its catastrophic condition,” stated Karolina Urban, PhD, Executive Vice President of Medical Affairs, Avicanna Inc. Dr. Urban further stated,
“These results are critical in helping guide us in the next steps in the further development of our medical products and pharmaceutical pipeline.”
